InMed Pharmaceuticals Inc.

INM

$1.60

+$0.92 (135.05%)

Closed

InMed to merge with Mentari Therapeutics in all-stock deal with $290 million placement funding migraine-focused company through 2028

Loading chart...

IndexN/A

Market Cap0.00B

Enterprise Value-0.01B

Income$-0.01B

Sales$0.00B

EmployeesN/A

P/E-1.09

P/S0.64

P/B0.17

P/C-0.41

EV/EBITDA1.50

EV/SalesN/A

EPS (ttm)-1.47

EarningsN/A

Gross Margin34.53%

Oper. Margin-160.20%

Profit Margin-165.14%

Volume91.54M

Shs Outstand0.00B

Change135.05%

Dividend Est.N/A

Dividend Ex-DateN/A

Perf YTDN/A

Perf YearN/A

Perf 3YN/A

Perf 5YN/A

Perf 10YN/A

IPON/A

Yesterday06:26PMSHAREHOLDER NOTICE: Brodsky & Smith Announces an Investigation of InMed Pharmaceuticals, Inc. (Nasdaq – INM)(globenewswire.com)03:00PM/C O R R E C T I O N -- InMed Pharmaceuticals/(gurufocus.com)11:00AMINM Stock Alert: Halper Sadeh LLC is Investigating Whether InMed Pharmaceuticals, Inc. is Obtaining a Fair Price for its Shareholders(gurufocus.com)10:56AMINM Stock Alert: Halper Sadeh LLC is Investigating Whether InMed Pharmaceuticals, Inc. is Obtaining a Fair Price for its Shareholders(businesswire.com)

Insider Trading

No insider trades found for INM.

InMed Pharmaceuticals Inc., a clinical stage pharmaceutical company, researches and develops cannabinoid-based therapies. The company's lead product is INM-755, a cannabinol topical cream, which is in a second Phase I clinical trials for the treatment of epidermolysis bullosa. The company is also involved in developing INM-088, which is in preclinical studies for the treatment of glaucoma; and INM-405 for the treatment of pain. In addition, it engages in the development of cannabinoid-based treatments for various diseases, including dermatology and ocular diseases. Further, the company works on IND-enabling pharmacology and preclinical toxicology studies; and IntegraSyn, an integrated biosynthesis-based manufacturing approach, for synthesizing pharmaceutical-grade cannabinoids. It has a research collaboration agreement with BayMedica Inc. for the manufacturing and testing of novel cannabinoid therapeutics. The company was formerly known as Cannabis Technologies Inc. and changed its name to InMed Pharmaceuticals Inc. in October 2014. InMed Pharmaceuticals Inc. was incorporated in 1981 and is headquartered in Vancouver, Canada.

CEO: Eric A. Adams Chem.Employees: 13www.inmedpharma.com

Metric	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018
Revenue	$4.94M	$4.60M	$4.14M	$1.09M	N/A	N/A	N/A	N/A
Cost of Revenue	$3.24M	$3.50M	$2.73M	$545.89K	N/A	$183.09K	$93.94K	$92.78K
Gross Profit	$1.71M	$1.10M	$1.40M	$543.55K	N/A	$-183.09K	$-93.94K	$-92.78K
Gross Margin	34.53%	23.94%	33.93%	49.89%	0.00%	0.00%	0.00%	0.00%
Operating Expenses	$9.62M	$9.24M	$9.78M	$14.34M	$12.17M	$8.97M	$10.26M	$6.69M
Operating Income	$-7.92M	$-8.13M	$-8.38M	$-13.79M	$-12.17M	$-9.15M	$-10.36M	$-6.78M
Operating Margin	-160.20%	-176.92%	-202.60%	-1265.95%	0.00%	0.00%	0.00%	0.00%
Net Income	$-8.16M	$-7.68M	$-7.95M	$-18.60M	$-12.65M	$-8.94M	$-10.01M	$-6.71M
Net Margin	-165.14%	-166.94%	-192.18%	-1707.32%	0.00%	0.00%	0.00%	0.00%
EPS (Basic)	$-11.44	$-27.55	$-86.00	$-21350.51	$-938.91	$-1161.21	$-1264.97	$-1032.30
EBITDA	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Stock Option Compensation Expense	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Price To Earnings Ratio	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Price To Sales Ratio	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Shares Outstanding	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Market Capitalization	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

InMed Pharmaceuticals Inc.

Insider Trading

Discover more